10-Q: Phio Pharmaceuticals Reports Q3 2024 Results, Cites Progress in Clinical Trial and Cost Rationalization

Phio Pharmaceuticals reported its Q3 2024 financial results, highlighting progress in its PH-762 clinical trial and the impact of cost rationalization efforts.

Summary

• Phio Pharmaceuticals, a clinical-stage biotechnology company, released its financial results for the third quarter of 2024, ending September 30.
• The company reported a net loss of $1.524 million for the quarter and $5.524 million for the nine-month period.
• Operating expenses totaled $1.590 million for the quarter and $5.713 million for the nine-month period, with research and development expenses significantly decreasing due to cost rationalization.
• The company's cash and cash equivalents stood at $5.390 million as of September 30, 2024.
• Phio completed a financing in July 2024, raising approximately $2.646 million in net proceeds.
• The company is currently conducting a Phase 1b clinical trial for its lead product candidate, PH-762, with five patients enrolled in the first two cohorts.
• Phio terminated its clinical co-development agreement with AgonOx in May 2024, ending its financial obligations and future milestone payments related to the collaboration.
• The company has implemented cost rationalization measures, including a reduction in headcount by approximately 36% and the closure of its corporate headquarters, transitioning to a primarily remote business.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the company's significant losses, limited cash runway, and the going concern warning. While there is some positive progress in the clinical trial and cost rationalization, the financial risks outweigh the positives.

Positives

• The company successfully raised $2.646 million through a financing in July 2024.
• The Phase 1b clinical trial for PH-762 is progressing with no reported adverse events in the first two cohorts.
• Cost rationalization efforts have significantly reduced research and development expenses.
• The company has a clear focus on product development, particularly with PH-762.
• The company has extended its lease for a laboratory facility in Worcester, Massachusetts until February 28, 2025.

Negatives

• The company reported a net loss of $1.524 million for the third quarter of 2024 and $5.524 million for the nine months ended September 30, 2024.
• The company has limited cash resources and has reported recurring losses since inception.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company terminated its clinical co-development agreement with AgonOx, losing potential future milestone and royalty payments.
• The company has negative operating cash flows and has not yet received product revenues.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• There is no guarantee that additional funding will be available on acceptable terms or at all.
• The company may need to scale back or terminate operations if it fails to obtain additional funding.
• The company is subject to the risks associated with clinical trials, including potential delays and adverse results.
• The company may not be able to maintain compliance with the continued listing requirements of The Nasdaq Capital Market.
• The company's stock price could be adversely affected by a delisting from Nasdaq.

Future Outlook

The company expects its cash and cash equivalents to fund its current operating plan into Q2 2025 and anticipates research and development and general and administrative expenses to remain relatively consistent for the remainder of 2024. The company will continue to assess its cash and future funding requirements and will seek additional funding to sustain future operations.

Management Comments

• The company implemented a cost rationalization program driven by its transition from a research company to a product development company.
• The company believes that direct-to-tumor administration of PH-762 resulted in activity against distant untreated tumors, indicative of a systemic anti-tumor response.
• The company believes its INTASYL compounds can improve immune cells to make them more effective in killing cancer.

Industry Context

Phio's focus on immuno-oncology therapeutics aligns with the broader industry trend of developing novel cancer treatments that leverage the body's immune system. The company's INTASYL technology and its application in T-cell therapies are part of the growing interest in personalized medicine and targeted therapies. The termination of the AgonOx collaboration reflects the challenges and risks inherent in biotech partnerships, where strategic shifts and financial considerations can lead to changes in development plans.

Comparison to Industry Standards

• Phio's cash burn rate is typical for a clinical-stage biotech company, but the company's cash runway is shorter than some of its peers, such as companies with larger market caps and more advanced clinical programs like Iovance Biotherapeutics (IOVA) or Adaptimmune Therapeutics (ADAP).
• The company's focus on intratumoral injection of PH-762 is a differentiated approach compared to systemic antibody therapies, which are more common in the immuno-oncology space, such as those developed by Bristol Myers Squibb (BMY) or Merck (MRK).
• The termination of the AgonOx collaboration is not uncommon in the biotech industry, where partnerships can be terminated due to strategic shifts or financial constraints, similar to other companies that have restructured their collaborations, such as those seen in the CAR-T cell therapy space.
• Phio's cost rationalization efforts, including headcount reduction and facility closures, are similar to actions taken by other biotech companies facing financial pressures, such as those seen in the recent restructuring announcements by companies like Agenus (AGEN) or Gritstone bio (GRTS).

Management Changes

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment if the company cannot secure additional funding.
• Employees have experienced a reduction in headcount as part of the cost rationalization program.
• Customers and suppliers may be impacted by the company's financial instability and potential operational changes.
• Creditors face the risk of non-payment if the company is unable to continue as a going concern.

Next Steps

• The company will continue to enroll patients in its Phase 1b clinical trial for PH-762, with expected completion of enrollment in the third quarter of 2025.
• The company will continue to assess its cash and cash equivalents and future funding requirements.
• The company will seek additional funding to sustain its future operations.

Key Dates

Keywords

Phio Pharmaceuticals, INTASYL, PH-762, Clinical Trial, Immuno-oncology, Biotechnology, Cost Rationalization, PD-1, T cells, Financing